Have a personal or library account? Click to login

Trigger points in medical practice - current therapeutic directions

Open Access
|Dec 2022

References

  1. 1. Do TP, Heldarskard GF, Kolding LT, Hvedstrup J, Schytz HW. Myofascial trigger points in migraine and tension-type headache. J Headache Pain. 2018;19(1):84; DOI:10.1186/s10194-018-0913-8.
  2. 2. Jutrzenka-Jesion J, Chochowska M, Hojan-Jezierska D. Fizjoterapia w leczeniu mięśniowo-powięziowych punktów spustowych. Physiotherapy in the treatment of myofascial trigger points. Hygeia Public Health. 2018;53(4):340-347.
  3. 3. Bron C, Dommerholt JD. Etiology of myofascial trigger points. Curr Pain Headache Rep. 2012;16(5):439-44; DOI:10.1007/s11916-012-0289-4.
  4. 4. Weller JL, Comeau D, Otis JAD. Myofascial Pain. Semin Neurol. 2018;38(6):640-643; DOI:10.1055/s-0038-1673674.
  5. 5. Furlan AD, van Tulder MW, Cherkin DC, Tsukayama H, Lao L, Koes BW, Berman BM. Acupuncture and dry-needling for low back pain. Cochrane Database Syst Rev. 2005;1:CD001351; DOI:10.1002/14651858. CD001351.pub2.
  6. 6. Nicpoń KW. Bóle mięśniowe i kurcze bolesne w praktyce neurologa. Pol Prz Neurol. 2007; 3(4):237-248.
  7. 7. Akamatsu FE, Yendo TM, Rhode C, Itezerote AM, Hojaij F, Andrade M, Hsing WT, Jacomo AL. Anatomical basis of the myofascial trigger points of the gluteus maximus muscle. Biomed Res Int. 2017;2017:4821968; DOI:10.1155/2017/4821968.
  8. 8. Wada JT, Akamatsu F, Hojaij F, Itezerote A, Scarpa JC, Andrade M, Jacomo A. An anatomical basis for the myofascial trigger points of the abductor hallucis muscle. Biomed Res Int. 2020;2020:9240581; DOI:10.1155/2020/9240581.
  9. 9. Alvarez DJ, Rockwell PG. Trigger points: diagnosis and management. Am Fam Physician. 2002;65(4):653-60.
  10. 10. Visser B, van Dieёn JH. Pathophysiology of upper extremity muscle disorders. J Electromyogr Kinesiol. 2006;16(1):1-16; DOI:10.1016/j.jelekin.2005.06.005.
  11. 11. Shah JP, Thaker N, Heimur J, Aredo JV, Sikdar S, Gerber L. Myofascial trigger points then and now: a historical and scientific perspective. PM R.;7(7):746-761; DOI:10.1016/j.pmrj.2015.01.024.
  12. 12. Hsieh YL, Hong CZ, Liu SY, Chou LW, Yang CC. Acupuncture at distant myofascial trigger spots enhances endogenous opioids in rabbits: a possible mechanism for managing myofascial pain. Acupunct Med. 2016;34(4):302-9; DOI:10.1136/acupmed-2015-011026.
  13. 13. Treaster D, Marras WS, Burr D, Sheedy JE, Hart D. Myofascial trigger point development from visual and postural stressors during computer work. J Electromyogr Kinesiol. 2006;16(2):115-24; DOI:10.1016/j.jelekin.2005.06.016.
  14. 14. Domżał TM. Przewlekłe nieswoiste bóle krzyża – stara dolegliwość czy nowa choroba neurologiczna? Pol Prz Neurol. 2007;3(4):216-227.
  15. 15. Muscolino J.E. Badanie palpacyjne układów mięśniowego i kostnego z uwzględnieniem punktów spustowych, stref odruchowych i stretchingu. 2nd ed. Wrocław: Edra Urban & Partner; 2016. 570 p.
  16. 16. Chochowska M, Ogrodowczyk R, Klonowska J, Marcinkowski JT. Tension headache and myofascial pain syndrome. Part II. Drug-free treatment – trigger point release (manual therapy). Hygeia Public Health. 2015;50(2):288-93.
  17. 17. Sharp H, Mize BB. Zeroing in on myofascial pain. Contemporary OB/GYN. 2011;56(8):30.
  18. 18. Kim JY, Choo YJ, Chang MC. Ultrasound-guided 3-in-1 trigger point injection for treating myofascial pain syndrome in muscles of the lateral scapular area: a case report. Ann Palliat Med. 2022;11(8):2785-2788; DOI:10.21037/apm-22-189.
  19. 19. Karadaş Ö, Gül HL, Inan LE. Lidocaine injection of pericranial myofascial trigger points in the treatment of frequent episodic tension-type headache. J Headache Pain. 2013;14(1):44; DOI:10.1186/1129-2377-14-44.
  20. 20. Albagieh H, Aloyouny A, Alshehri N, Alsammahi N, Almutrafi D, Hadlaq E. Efficacy of lidocaine versus mepivacaine in the management of myofascial pain. Saudi Pharm J. 2020;28(10):1238-1242; DOI:10.1016/j. jsps.2020.08.014.
  21. 21. Tantanatip A, Patisumpitawong W, Lee S. Comparison of the effects of physiologic saline interfascial and lidocaine trigger point injections in treatment of myofascial pain syndrome: a double-blind randomized controlled trial. Arch Rehabil Res Clin Transl. 2021;3(2):100119; DOI:10.1016/j.arrct.2021.100119.
  22. 22. Ghasemi M, Mosaffa F, Hoseini B, Behnaz F. Comparison of the effect of bicarbonate, hyaluronidase, and lidocaine injection on myofascial pain syndrome. Anesth Pain Med. 2020;10(3):e101037; DOI:10.5812/aapm.101037.
  23. 23. Lugo LH, García HI, Rogers HL, Plata JA. Treatment of myofascial pain syndrome with lidocaine injection and physical therapy, alone or in combination: a single blind, randomized, controlled clinical trial. BMC Musculoskelet Disord. 2016;17:101; DOI: 10.1186/s12891-016-0949-3.
  24. 24. Suputtitada A, Chen CPC, Ngamrungsiri N, Schmitz C. Effects of repeated injection of 1% lidocaine vs. radial extracorporeal shock wave therapy for treating myofascial trigger points: a randomized controlled trial. Medicina (Kaunas). 2022;58(4):479; DOI:10.3390/medicina58040479.
  25. 25. Öwczarek-Drabińska JE, Zielińska I. Temporomandibular disorders and kinesiotaping: literature review. Prosthodontics. 2022;72(1):59-67; DOI:10.5114/ps/147494.
  26. 26. Dessie SG, Von Bargen E, Hacker MR, Haviland MJ, Elkadry E. A randomized, double-blind, placebo-controlled trial of onabotulinumtoxin A trigger point injections for myofascial pelvic pain. Am J Obstet Gynecol. 2019;221(5):517.e1-517.e9; DOI:10.1016/j.ajog.2019.06.044.
  27. 27. Ranoux D, Martiné G, Espagne-Dubreuilh G, Amilhaud-Bordier M, Caire F, Magy L. OnabotulinumtoxinA injections in chronic migraine, targeted to sites of pericranial myofascial pain: an observational, open label, real-life cohort study. J Headache Pain. 2017;18(1):75; DOI:10.1186/s10194-017-0781-7.
  28. 28. Janis JE, Dhanik A, Howard JH. Validation of the peripheral trigger point theory of migraine headaches: single-surgeon experience using botulinum toxin and surgical decompression. Plast Reconstr Surg. 2011;128(1):123-131; DOI:10.1097/PRS.0b013e3182173d64.
  29. 29. Qerama E, Fuglsang-Frederiksen A, Kasch H, Bach FW, Jensen TS. A double-blind, controlled study of botulinum toxin A in chronic myofascial pain. Neurology. 2006;67(2):241-5; DOI:10.1212/01. wnl.0000224731.06168.df.
  30. 30. Ho KY, Tan KH. Botulinum toxin A for myofascial trigger point injection: a qualitative systematic review. Eur J Pain. 2007;11(5):519-27; DOI:10.1016/j.ejpain.2006.09.002.
  31. 31. Lucena-Anton D, Luque-Moreno C, Valencia-Medero J, Garcia-Munoz C, Moral-Munoz JA. Effectiveness of dry needling of myofascial trigger points in the triceps surae muscles: systematic review. Healthcare (Basel). 2022;10(10):1862; DOI:10.3390/healthcare10101862.
  32. 32. Gattie E, Cleland JA, Snodgrass S. The effectiveness of trigger point dry needling for musculoskeletal conditions by physical therapists: a systematic review and meta-analysis. J Orthop Sports Phys Ther. 2017;47(3):133-149; DOI:10.2519/jospt.2017.7096.
  33. 33. Tough EA, White AR, Cummings TM, Richards SH, Campbell JL. Acupuncture and dry needling in the management of myofascial trigger point pain: a systematic review and meta-analysis of randomised controlled trials. Eur J Pain. 2009;13(1):3-10; DOI:10.1016/j.ejpain.2008.02.006.
  34. 34. Cagnie B, Barbe T, De Ridder E, Van Oosterwijck J, Cools A, Danneels L. The influence of dry needling of the trapezius muscle on muscle blood flow and oxygenation. J Manipulative Physiol Ther. 2012;35(9):685-91; DOI:10.1016/j.jmpt.2012.10.005.
  35. 35. Navarro-Santana MJ, Sanchez-Infante J, Fernández-de-Las-Peñas C, Cleland JA, Martín-Casas P, Plaza-Manzano G. Effectiveness of dry needling for myofascial trigger points associated with neck pain symptoms: an updated systematic review and meta-analysis. J Clin Med. 2020;9(10):3300; DOI:10.3390/jcm9103300.
  36. 36. Quintner JL, Bove GM, Cohen ML. A critical evaluation of the trigger point phenomenon. Rheumatology (Oxford). 2015;54(3):392-9; DOI:10.1093/rheumatology/keu471.
  37. 37. Tanoğlu C, Duman İlki C, Ersoy A, Yaşar H. Trigger point injection as a rare cause of sschemic stroke: a case report. Neurologist. 2022;27(4):203-205; DOI:10.1097/NRL.0000000000000373.
  38. 38. Rajfur K. Znaczenie wybranych metod leczenia zachowawczego w niwelowaniu objawów przewlekłego zespołu bólowego dolnego odcinka kręgosłupa. Öpole: Wydawnictwo Uniwersytetu Medycznego; 2000. 55 p.
  39. 39. Woźnica D. Porównanie rozszerzonych kompetencji zawodowych wśród fizjoterapeutów w Europie. Physiotherapy Review. 2020;24(4):52-58; DOI:10.5114/phr.2020.102692.
  40. 40. Śharkey J. Igłoterapia – podręcznik. Śuche igłowanie w terapii mięśniowo-powięziowych punktów spustowych. 2019. Poznań: Wydawnictwo WSEiT; 2019. 263 p.
  41. 41. Śławek J, Bogucki A, Budrewicz Ś, Drużdż A, Koziorowski D, Krawczyk M Öchudło ŚG. Leczenie toksyną botulinową spastyczności kończyny dolnej po udarze mózgu - rekomendacje Śekcji Śchorzeń Pozapiramidowych Polskiego Towarzystwa Neurologicznego, Polskiego Towarzystwa Choroby Parkinsona i Innych Zaburzeń Ruchowych oraz Interdyscyplinarnej Grupy Ekspertów. Pol Prz Neurol. 2016;12(2):65-79.
  42. 42. Szwed M, Szwed J, Dzikowski M. Botulinum toxin (BoNT) in the correction of mimic wrinkles - the most common complications. J Educ Health Sport. 2022;12(8):714:21; DOI: 10.12775/JEHS.2022.12.08.072.
  43. 43. Śiastała K. Metody rewitalizacji okolic oczu toksyną botulinową z punktu widzenia lekarza okulisty. 2019. Kosmet. Estet. 2019;1(8):111-15.
  44. 44. Torp KD, Metheny E, Simon LV. Lidocaine Toxicity [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 [cited 2022 Nov 20]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482479/
  45. 45. Boyce D, Wempe H, Campbell C, Fuehne S, Zylstra E, Smith G, Wingard C, Jones R. Adverse events associated with therapeutic dry needling. Int J Sports Phys Ther. 2020;15(1):103-113.
  46. 46. Kearns G, Gilbert KK, Allen B, Sizer PS Jr, Brismée JM, Pendergrass T, Lierly M, York D. Accuracy and safety of dry needle placement in the piriformis muscle in cadavers. J Man Manip Ther. 2018;26(2):89-96; DO I:10.1080/10669817.2017.1346745.
Language: English
Page range: 129 - 137
Submitted on: Nov 20, 2022
Accepted on: Nov 29, 2022
Published on: Dec 31, 2022
Published by: Foundation for Cell Biology and Molecular Biology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2022 Marta Wanat, Bernadetta Nowak, Ada Świątko, Karol Mirkowski, Jurand Domański, Paweł Dąbrowski, Zygmunt Domagała, published by Foundation for Cell Biology and Molecular Biology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.